Year-end trading statement

AI SummaryClose X

Fusion Antibodies plc reported unaudited revenues of £2.13 million for the financial year ended 31 March 2026, an increase of approximately 9% from £1.96 million in the prior year, with a significant improvement in gross margin to 50% (FY2025: 22%), or 43% underlying. The company's cash position strengthened to £1.04 million as of 31 March 2026, up from £0.4 million. Key developments include the grant of a U.S. patent for its OptiMAL® platform, continued progress with the National Cancer Institute, and securing new projects with global pharmaceutical companies, alongside an IP transfer to Finn Therapeutics for £250,000. The company is positioning for growth through platform development and strategic partnerships, with a cautiously optimistic outlook for FY2027.

Disclaimer*

UK 100

Latest directors dealings